Semaglutide is a GLP-1 receptor agonist sold as Wegovy and Ozempic; trials show roughly 15% average weight loss.
Semaglutide is a once-weekly GLP-1 receptor agonist. In the STEP trials, semaglutide 2.4 mg produced about 15% average weight loss over 68 weeks. FDA-approved brands are Wegovy (weight management) and Ozempic (type 2 diabetes). Compounded semaglutide is a different, non-FDA-approved product.
The FDA resolved the tirzepatide (Dec 2024) and semaglutide (Feb 2025) shortages, and wind-down deadlines passed in 2025. On Apr 30, 2026 the FDA proposed excluding these drugs from the 503B bulks list (comment closed Jun 29, 2026). Patient-specific 503A compounding continues only narrowly, and cost alone is not a clinical need. Full regulatory status →
Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. The FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Primary source: FDA — Human Drug Compounding.